Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) traded down 3.2% during trading on Monday . The stock traded as low as $10.41 and last traded at $10.44. 45,861 shares changed hands during trading, a decline of 53% from the average session volume of 97,472 shares. The stock had previously closed at $10.79.
Gyre Therapeutics Stock Down 9.8 %
The company's 50 day simple moving average is $12.40 and its two-hundred day simple moving average is $12.68.
Insiders Place Their Bets
In other Gyre Therapeutics news, President Songjiang Ma sold 2,000 shares of the business's stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $12.70, for a total transaction of $25,400.00. Following the sale, the president now owns 2,928,467 shares in the company, valued at approximately $37,191,530.90. The trade was a 0.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders sold 12,000 shares of company stock valued at $143,480. 19.52% of the stock is currently owned by corporate insiders.
Institutional Trading of Gyre Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the business. Barclays PLC raised its holdings in shares of Gyre Therapeutics by 281.8% during the third quarter. Barclays PLC now owns 9,288 shares of the company's stock worth $116,000 after purchasing an additional 6,855 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Gyre Therapeutics by 16.9% during the 3rd quarter. Geode Capital Management LLC now owns 303,647 shares of the company's stock valued at $3,808,000 after buying an additional 43,840 shares during the last quarter. State Street Corp lifted its holdings in shares of Gyre Therapeutics by 8.8% in the 3rd quarter. State Street Corp now owns 104,490 shares of the company's stock valued at $1,310,000 after buying an additional 8,412 shares during the period. FMR LLC purchased a new stake in shares of Gyre Therapeutics in the third quarter worth about $47,000. Finally, Advantage Alpha Capital Partners LP purchased a new position in Gyre Therapeutics during the third quarter valued at approximately $334,000. 23.99% of the stock is currently owned by institutional investors and hedge funds.
About Gyre Therapeutics
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Read More
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
